- IBD
-
Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
-
Natalie Grace Fairhurst, Simon P. L. Travis
-
Intest Res 2018;16(2):209-215. Published online April 30, 2018
-
DOI: https://doi.org/10.5217/ir.2018.16.2.209
-
-
Abstract
PDF PubReader ePub
Faecal microbiota transplantation (FMT) has recently re-emerged as a viable therapeutic option for colonic disorders. Its efficacy has been proved in the treatment of Clostridium difficile infection which has encouraged research into the use of FMT for other disorders involving gut dysbiosis, such as ulcerative colitis (UC), a chronic inflammatory disease characterized by relapsing and remitting colonic inflammation. Although the FMT protocol for C. difficile treatment is well established, there are numerous additional factors to consider when applying FMT to treat inflammatory diseases. Various studies have attempted to address these factors but technical inconsistency between reports has resulted in a failure to achieve clinically significant findings. Case reports of FMT in UC have shown favorable outcomes yet demonstrating these effects on a larger scale has proved difficult. The following review aims to explore these issues and to analyze why they may be hindering the progression of FMT therapy in UC.
-
Citations
Citations to this article as recorded by 
- The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M.M. Quigley, Bincy P. Abraham Digestive Diseases.2023; 41(4): 656. CrossRef - Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches
Jana Štofilová, Monika Kvaková, Anna Kamlárová, Emília Hijová, Izabela Bertková, Zuzana Guľašová Biomedicines.2022; 10(9): 2236. CrossRef - Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience
M.C. Flux, Christopher A. Lowry Neurobiology of Disease.2020; 135: 104578. CrossRef - In Situ Profiling of the Three Dominant Phyla Within the Human Gut Using TaqMan PCR for Pre-Hospital Diagnosis of Gut Dysbiosis
Young Jae Jo, Setu Bazie Tagele, Huy Quang Pham, YeonGyun Jung, Jerald Conrad Ibal, SeungDae Choi, Gi-Ung Kang, Sowon Park, Yunkoo Kang, Seung Kim, Hong Koh, Jae-Ho Shin International Journal of Molecular Sciences.2020; 21(6): 1916. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Stephanie A. Flowers, Shubha Bhat, James C. Lee Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020; 40(7): 704. CrossRef - Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu Intestinal Research.2019; 17(1): 78. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho Intestinal Research.2019; 17(1): 6. CrossRef - Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Xiao Ding, Qianqian Li, Pan Li, Ting Zhang, Bota Cui, Guozhong Ji, Xiang Lu, Faming Zhang Drug Safety.2019; 42(7): 869. CrossRef
-
7,249
View
-
79
Download
-
11
Web of Science
-
9
Crossref
|